Cellectar Biosciences, Inc. CLRB
Set alert
1.22 USD +0.01 +1.24%
At close · Nov 2
1.20 -0.02 -1.64%
After hours · Nov 2, 4:00 PM ET
1.18 Day range 1.26
1.12 52-week range 4.70
- YTD
- -58.64%
- 1 year
- -64.01%
- Open
- 1.23
- Prev close
- 1.21
- Mkt cap
- 11.53M
- Vol
- 66.55K
- Avg vol
- 87.09K
- EPS
- -3.46
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.18
- High
- 1.26
- Forward P/E
- -0.10
- Beta
- 1.01
- Short ratio
- 8.34
- Inst. own
- 34.55%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.60
- 200-d avg
- 2.48
- 1y target
- 5.67
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 3 months ago |
| SMA: Bearish | Aug 4, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
Analyst view
Consensus: buy
Buy
Price target (mean) 5.67 +364.5% upside
Now 1.22
- Target (low)
- 1.00
- Target (mean)
- 5.67
- Target (high)
- 13.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 3
- 2 months ago 3
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.3525 | -0.43 – -0.32 | -0.40 | +11.9% | 0 | 0.0% | 4 |
| Next quarter | -0.195 | -0.26 – -0.16 | -0.74 | +73.7% | 0 | 0.0% | 4 |
| Current year | -1.57 | -1.73 – -1.39 | -3.11 | +49.6% | 0 | 0.0% | 4 |
| Next year | -0.6825 | -0.77 – -0.63 | -1.57 | +56.5% | 10.09M | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Oppenheimer | Downgrade | Outperform | Perform |
| Nov 19, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 28, 2024 | Roth MKM | Maintained | Buy | Buy |
| Mar 28, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 4, 2024 | Roth MKM | Reiterated | Buy | Buy |
| Nov 4, 2022 | HC Wainwright & Co. | Maintained | — | Buy |